Literature DB >> 21270326

Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.

Marcus A Rosencrantz1, Mickey S Coffler, Annette Haggan, Kimberly B Duke, Michael C Donohue, Rana F Shayya, H Irene Su, R Jeffrey Chang.   

Abstract

CONTEXT: In women with polycystic ovary syndrome (PCOS), the basis for ovarian androgen overproduction involves an overall increase of steroidogenesis, notably in the delta-4 pathway. However, in vitro studies have suggested that excessive androgen production occurs predominantly through the delta-5 pathway.
OBJECTIVE: This study was performed to assess androgen dose-responses after human chorionic gonadotropin (hCG) stimulation in PCOS and normal women.
DESIGN: We conducted a prospective study to compare androgen production after iv hCG in PCOS and normal women.
SETTING: The study was conducted in a General Clinical Research Center in an academic medical center. PARTICIPANTS: Women with PCOS (age, 18-37 yr; n = 10) and normal ovulatory controls (age, 18-37 yr; n = 11) were recruited.
INTERVENTIONS: For dose-response studies, blood samples were obtained before and at 0.5, 24, and 48 h after iv recombinant hCG (1, 10, 25, 100, and 250 μg). A subset of subjects underwent frequent blood sampling over 24 h after iv injection of 25 μg of recombinant hCG. MAIN OUTCOME MEASURE(S): We measured basal and stimulated serum 17-hydroxyprogesterone (17-OHP), androstenedione (A), testosterone (T), dehydroepiandrosterone, estradiol, and progesterone responses after hCG administration.
RESULTS: In PCOS women, maximal A and T production was observed at the lowest doses of hCG, whereas responses were minimal in normal women. Incremental responses of 17-OHP, estradiol, and progesterone were greater in PCOS compared to normal women.
CONCLUSION: In PCOS women, maximal A and T responses to hCG relative to those of 17-OHP are consistent with ovarian androgen overproduction via the delta-5 pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270326      PMCID: PMC3070255          DOI: 10.1210/jc.2010-2200

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  33 in total

1.  Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells.

Authors:  J F Cara; R L Rosenfield
Journal:  Endocrinology       Date:  1988-08       Impact factor: 4.736

2.  Missense mutation serine106----proline causes 17 alpha-hydroxylase deficiency.

Authors:  D Lin; J A Harikrishna; C C Moore; K L Jones; W L Miller
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

Review 3.  Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome.

Authors:  R L Rosenfield; R B Barnes; J F Cara; A W Lucky
Journal:  Fertil Steril       Date:  1990-05       Impact factor: 7.329

4.  Kinetic studies on ovarian C-17,20-lyase activity: effect of luteinizing hormone surge.

Authors:  B Eckstein; O Greenbaum; S Cohen
Journal:  Endocrinology       Date:  1985-12       Impact factor: 4.736

5.  Androgen synthesis during follicular development: evidence that rat granulosa cell 17-ketosteroid reductase is independent of hormonal regulation.

Authors:  K Bogovich; J S Richards
Journal:  Biol Reprod       Date:  1984-08       Impact factor: 4.285

6.  Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism.

Authors:  R L Barbieri; A Makris; R W Randall; G Daniels; R W Kistner; K J Ryan
Journal:  J Clin Endocrinol Metab       Date:  1986-05       Impact factor: 5.958

7.  Steroidogenic response to a single injection of hCG in pre- and early pubertal cryptorchid boys.

Authors:  J Tapanainen; H Martikainen; L Dunkel; J Perheentupa; R Vihko
Journal:  Clin Endocrinol (Oxf)       Date:  1983-04       Impact factor: 3.478

8.  A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.

Authors:  J E Nestler; L P Powers; D W Matt; K A Steingold; S R Plymate; R S Rittmaster; J N Clore; W G Blackard
Journal:  J Clin Endocrinol Metab       Date:  1991-01       Impact factor: 5.958

9.  Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin.

Authors:  C Bergh; B Carlsson; J H Olsson; U Selleskog; T Hillensjö
Journal:  Fertil Steril       Date:  1993-02       Impact factor: 7.329

10.  Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.

Authors:  R B Barnes; R L Rosenfield; S Burstein; D A Ehrmann
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

View more
  8 in total

Review 1.  Disordered follicle development.

Authors:  R Jeffrey Chang; Heidi Cook-Andersen
Journal:  Mol Cell Endocrinol       Date:  2012-07-31       Impact factor: 4.102

2.  The effect of clomiphene citrate, herbal mixture, and herbal mixture along with clomiphene citrate on clinical and para-clinical parameters in infertile women with polycystic ovary syndrome: a randomized controlled clinical trial.

Authors:  Nava Ainehchi; Arash Khaki; Elaheh Ouladsahebmadarek; Mohamad Hammadeh; Laya Farzadi; Azizeh Farshbaf-Khalili; Solmaz Asnaashari; Hossein Jabbari Khamnei; Amir Afshin Khaki; Majid Shokoohi
Journal:  Arch Med Sci       Date:  2020-02-25       Impact factor: 3.318

3.  Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women.

Authors:  Divya K Shah; Stacey A Missmer; Katharine F B Correia; Elizabeth S Ginsburg
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958

4.  Lack of Serum anti-Mullerian hormone responses after recombinant human chorionic gonadotropin stimulation in women with polycystic ovary syndrome.

Authors:  Heidi Cook-Andersen; Sandy S Chuan; Kevin Maas; Marcus A Rosencrantz; H Irene Su; Mark Lawson; Helen D Mason; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

5.  Decreased inhibin B responses following recombinant human chorionic gonadotropin administration in normal women and women with polycystic ovary syndrome.

Authors:  Rana F Shayya; Marcus A Rosencrantz; Sandy S Chuan; Heidi Cook-Andersen; William E Roudebush; H Irene Su; Shunichi Shimasaki; R Jeffrey Chang
Journal:  Fertil Steril       Date:  2013-11-01       Impact factor: 7.329

6.  Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry.

Authors:  Candace C Keefe; Mildred M Goldman; Ke Zhang; Nigel Clarke; Richard E Reitz; Corrine K Welt
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

7.  Individual 17-Hydroxyprogesterone Responses to hCG Are Not Correlated With Follicle Size in Polycystic Ovary Syndrome.

Authors:  Michael V Homer; Tannaz Toloubeydokhti; Mark A Lawson; Gabriel Garzo; Antoni J Duleba; R Jeffrey Chang
Journal:  J Endocr Soc       Date:  2019-02-07

8.  DHEA and polycystic ovarian syndrome: Meta-analysis of case-control studies.

Authors:  Jiby Jolly Benjamin; MaheshKumar K; Teena Koshy; Maruthy K N; Padmavathi R
Journal:  PLoS One       Date:  2021-12-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.